The open-label study evaluated the safety and tolerability, biological activity, blood biomarkers and preliminary efficacy of COYA 301 in 8 patients with Alzheimer’s disease (AD). The ...
Researchers at Tsukuba University have discovered that the increase in regulatory T (Treg) cells, which typically suppress immune responses, does not adequately control elderly-onset rheumatoid ...
Understanding how regulatory T cells (Tregs) develop and work is key to determining how they might be manipulated to encourage the destruction of cancer cells or prevent autoimmunity. Cell behavior is ...
COYA 303 is an investigational biologic combination of COYA 301, Coya’s low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist (GLP-1RA), designed to deliver a multi-targeted immunomodulatory ...
Immune cells called regulatory T cells have long been known for their role in countering inflammation. In the setting of infection, these so-called Tregs restrain the immune system to ensure it ...
3D rendering of the tumor microenvironment. The recipe for a general and long-lasting cancer treatment could involve regulatory T cells, a type of white blood cell. This is the first installment in a ...
New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg ...
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with ...
Leonardo Ferreira, Ph.D., left, and graduate student Russell Cochrane envision CAR Tregs being useful in cancer, type 1 diabetes and organ transplants. A new paper from MUSC Hollings Cancer Center ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results